Selank
Heptapeptide researched for mood and cognitive support.
Selank
Background
Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, developed as a stabilized analog with an added tripeptide to extend its half-life. It has been studied for anxiolytic and nootropic properties, with proposed mechanisms involving modulation of GABAergic and monoaminergic systems and effects on the expression of brain-derived neurotrophic factor.
Most published research originates from Russian institutions, including behavioral and gene-expression studies in rodents and small clinical reports. Independent international replication is limited.
Selected literature
- Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank. Zhurnal Nevrologii i Psikhiatrii. 2008;108(4):38-48.
- Kolomin T, et al. Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank. Doklady Biochemistry and Biophysics. 2010;430:5-7.
- Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide selank on a conditioned active avoidance reflex in rats. Neuroscience and Behavioral Physiology. 2003;33(7):639-643.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
Selank was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences with the Zakusov Institute of Pharmacology. It has no registered Western pharmaceutical trademark or approved drug product. Catalyst Research Labs is not affiliated with these institutions. Supplied as reference material only.
